Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 365 Cr.
- Current Price ₹ 247
- High / Low ₹ 359 / 244
- Stock P/E 43.3
- Book Value ₹ 48.8
- Dividend Yield 0.81 %
- ROCE 13.5 %
- ROE 12.2 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 19.4%
Cons
- Working capital days have increased from 105 days to 169 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 95.27 | 95.15 | 78.47 | |
| 74.56 | 73.69 | 65.26 | |
| Operating Profit | 20.71 | 21.46 | 13.21 |
| OPM % | 21.74% | 22.55% | 16.83% |
| 1.00 | 1.05 | 1.34 | |
| Interest | 0.17 | 0.82 | 0.83 |
| Depreciation | 1.59 | 2.04 | 2.29 |
| Profit before tax | 19.95 | 19.65 | 11.43 |
| Tax % | 25.51% | 26.92% | 26.16% |
| 14.86 | 14.36 | 8.44 | |
| EPS in Rs | 10.03 | 9.70 | 5.70 |
| Dividend Payout % | 19.93% | 20.63% | 17.55% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 53% |
| 3 Years: | 39% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 14.81 | 14.81 | 14.81 |
| Reserves | 39.87 | 51.60 | 57.45 |
| 9.75 | 16.49 | 26.45 | |
| 19.34 | 16.17 | 11.16 | |
| Total Liabilities | 83.77 | 99.07 | 109.87 |
| 25.49 | 34.39 | 33.09 | |
| CWIP | 0.00 | 1.98 | 21.06 |
| Investments | 7.08 | 16.78 | 19.82 |
| 51.20 | 45.92 | 35.90 | |
| Total Assets | 83.77 | 99.07 | 109.87 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 9.16 | 14.99 | 16.54 | |
| -2.64 | 2.05 | -25.85 | |
| 3.96 | 2.56 | 7.40 | |
| Net Cash Flow | 10.49 | 19.60 | -1.91 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 72.33 | 51.56 | 71.17 |
| Inventory Days | 92.33 | 124.92 | 98.61 |
| Days Payable | 92.57 | 72.34 | 82.43 |
| Cash Conversion Cycle | 72.09 | 104.13 | 87.35 |
| Working Capital Days | 68.46 | 79.06 | 168.89 |
| ROCE % | 27.24% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 May - Newspaper publication of the Financial Results for the quarter and year ended 31st March 2024.
-
Re-Aappointment Of Internal Auditors
6 May - M/s. KR & Associates as Internal Auditors for conducting Internal Audit from FY 2024-25 onwards.
- Corporate Action-Board approves Dividend 6 May
- Results For The Quarter And Year Ended 31St March 2024 6 May
- Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th May 2024 6 May
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries